/

REPL

Replimune Group, Inc.Open

12.68−0.39 −2.98%USD

NasdaqGS · as of Oct 13, 10:18 ET · 15m delay

Open

12.91

Prev close

13.07

Day range

12.5312.93

52-week range

1.5016.33

Volume

88.85K0.02×

Mkt cap

1.19B

P/E ttm

—

Fwd P/E

-6.97

EPS ttm

-3.15

Div yield

0.00%

Earnings

Aug 14, 2026

From 52w high

−22.35%

Price Chart

Yahoo Finance · delayed

REPLOct 13, 2026O 12.91H 12.93L 12.52C 12.68−0.39 (−2.98%)Vol 88.85K

SMA 5013.84
SMA 2009.03

1Y change +179.91% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

REPL Replimune Group, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.30%
1 month: −1.86%
3 months: +28.47%
6 months: +550.26%
Year to date: +30.45%
1 year: +178.07%

Valuation & ownership

Market cap: 1.19B
Enterprise value: 1.15B
P/E (ttm): —
Forward P/E: -6.97
PEG ratio: —
Price / book: 10.08
Price / sales (ttm): —
EV / EBITDA: -3.95
EPS (ttm): -3.15
EPS (forward): -1.82
Beta (5y monthly): 0.94
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 94.22M
Float: 67.65M
Short % of float: 34.24%
Short ratio (days): 10.98
Held by insiders: 1.65%
Held by institutions: 105.76%
Avg volume (3m): 4.12M
50-day average: 13.82
200-day average: 9.01
52-week change: +178.07%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 43.3
vs 50-day SMA: −8.36%
vs 200-day SMA: +40.48%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.99%
Realised vol (20d, ann.): 37.8%
From 52-week high: −22.35%
From 52-week low: +745.33%

ANR

Analyst Consensus

6 analysts

Consensus

Buy

1.75 on a 1 (strong buy) – 5 (sell) scale

Mean target

19.50

+53.79% implied

Low 14.00Median 19.50High 24.00

Recommendation trend

Now7 / 0 / 1
1m ago7 / 0 / 1

DES

About Replimune Group, Inc.

Yahoo Finance profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 465
Headquarters: Woburn, MA, United States
Website: replimune.com
Officers: Dr. Sushil Patel Ph.D. CEO & Director
Ms. Emily Luisa Hill Chief Financial Officer
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. Chief Medical Officer
Mr. Philip Astley-Sparke F.S.A. Executive Chairman

SEAS

Seasonality · REPL

2018–2026 · monthly returns

Strongest month Oct +26.81%Weakest month Mar −10.07%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-27.7	8.8	0.0	-66.4	238.1	27.4	1.2	36.6	-13.5	-4.2			+30.5%
2025	15.4	-9.3	-23.1	0.3	-8.2	3.5	-24.3	-23.2	-22.4	132.2	2.8	-2.8	−19.7%
2024	-7.9	10.6	-4.8	-22.3	-17.0	70.8	11.1	1.7	7.8	7.3	19.7	-14.0	+43.7%
2023	2.4	-21.4	-19.4	-5.3	13.5	22.3	-9.3	-3.1	-16.2	-14.8	-23.3	-24.6	−69.0%
2022	-26.8	-19.1	5.9	-1.2	-13.4	20.3	10.3	-1.1	-9.4	6.3	11.5	32.9	+0.4%
2021	1.7	-10.7	-11.9	19.9	6.5	-1.4	-14.8	-3.0	-6.7	-0.4	-3.5	-4.9	−29.0%
2020	10.8	-12.8	-28.1	81.4	3.8	32.3	-19.6	35.2	-14.7	81.6	23.6	-26.2	+165.9%
2019	21.1	13.3	10.9	10.2	-19.4	8.4	-15.3	-16.4	33.9	22.3	-18.2	3.2	+43.5%
2018								28.7	-16.5	-20.0	16.4	-33.3	−33.3%

INSD

Insider Activity · REPL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

50K shares

Sells, 6 months

184.5K shares

Net shares

−134.5K

Net change in insider shares

−8.00%

Date	Insider	Transaction	Shares	Value
Aug 19, 2026	Astley-Sparke PhilipDirector	Stock Gift at price 0.00 per share.	50K	—
Aug 16, 2026	Hill Emily LuisaChief Financial Officer	Sale at price 14.28 per share.	9.3K	$132.18K
Aug 9, 2026	Hill Emily LuisaChief Financial Officer	Sale at price 12.97 per share.	11.4K	$148.48K
Aug 9, 2026	Patel SushilChief Executive Officer	Sale at price 12.97 per share.	39.3K	$510.25K
Aug 9, 2026	Xynos KonstantinosOfficer	Sale at price 12.97 per share.	11.4K	$148.47K
Aug 9, 2026	Schwendenman AndrewOfficer	Sale at price 12.97 per share.	7.6K	$98.99K
May 31, 2026	Sarchi ChristopherOfficer	Sale at price 9.24 per share.	12K	$110.88K
May 17, 2026	Hill Emily LuisaChief Financial Officer	Sale at price 5.08 per share.	7.8K	$39.69K
May 17, 2026	Patel SushilChief Executive Officer	Sale at price 5.08 per share.	37.3K	$189.61K
May 17, 2026	Xynos KonstantinosOfficer	Sale at price 5.08 per share.	14K	$71.24K
May 17, 2026	Schwendenman AndrewOfficer	Sale at price 5.08 per share.	7.9K	$40.10K
May 17, 2026	Sarchi ChristopherOfficer	Sale at price 5.08 per share.	8.6K	$43.82K
May 17, 2026	Astley-Sparke PhilipDirector	Sale at price 5.08 per share.	17.7K	$89.70K
Apr 1, 2026	Sarchi ChristopherOfficer	Sale at price 8.01 per share.	6.5K	$52.06K
Mar 31, 2026	Hill Emily LuisaChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	50K	—
Mar 31, 2026	Patel SushilChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	251.2K	—
Mar 31, 2026	Xynos KonstantinosOfficer	Stock Award(Grant) at price 0.00 per share.	50K	—
Mar 31, 2026	Schwendenman AndrewOfficer	Stock Award(Grant) at price 0.00 per share.	36.7K	—
Mar 31, 2026	Sarchi ChristopherOfficer	Stock Award(Grant) at price 0.00 per share.	50K	—
Mar 31, 2026	Astley-Sparke PhilipDirector	Stock Award(Grant) at price 0.00 per share.	50K	—

13F

Investors Holding REPL

latest 13F filings of 29 followed managers

Investors holding REPL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$440.6K	0.00%	39.80K	−90%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

REPL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

REPL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Replimune Group, Inc.

Seasonality · REPL

Insider Activity · REPL

Congress Trades · REPL

Investors Holding REPL

Investors Holding REPL

Congress Trades · REPL

Insider Activity · REPL

Seasonality · REPL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Replimune Group, Inc.

Financial Snapshot

Earnings & Dividends

News